A Phase 2 interventional study of S-600918 and Placebo to S-600918 in Chronic Cough, sponsored by Shionogi. Completed at 136 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-27.
Sponsored by Shionogi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Chronic Cough · United States.
Among the 44 studies in Chronic Cough with a site in United States, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2020, is one of 16 in phase 2, and was the 18th registered.
142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.
Browse Chronic Cough studies →9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
University of Montana · Sites in United States
Ages 18–99
Hyfe Inc · Sites in United States
Ages 21+
Medical University of South Carolina · Sites in United States
Ages 18+
University of Montana · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 50 across the 37 interventional studies, 35 across the 7 observational. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 1 study filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
3 of the studies in Chronic Cough with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110144Mayo ClinicEfficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough | 2026-12 |
| NCT05273190University of MinnesotaStimulation of the Larynx to Treat Unexplained Chronic Cough | 2027-06-01 |
| NCT06634823Medical University of South CarolinaEfficacy of Intramuscular Steroid Injection for Chronic Cough. | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Chronic Cough with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 50 mg S-600918 orally once a day for 28 days.
Drug: S-600918
Participants will receive 150 mg S-600918 orally once a day for 28 days.
Drug: S-600918
Participants will receive 300 mg S-600918 orally once a day for 28 days.
Drug: S-600918
Participants will receive placebo to S-600918 orally once a day for 28 days.
Drug: Placebo to S-600918
Tablets for oral administration
Also known as: Sivopixant
Tablets for oral administration
Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment
Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour in 24 hours at each visit with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the log-transformed coughs per hour in 24 hours at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.
Time frame: Baseline to Week 4
Number of Participants With 30%, 50%, and 70% Reduction in Number of Coughs Per Hour Over 24 Hours After 4 Weeks of Study Treatment
The number of coughs per hour for 24 hours was measured using a cough monitor.
Time frame: Baseline to Week 4
Percent Change in Number of Coughs Per Hour While Awake Following 4 Weeks of Study Treatment
Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while awake at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while awake at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.
Time frame: Baseline to Week 4
Number of Participants With 30%, 50% and 70% Reduction in Number of Coughs Per Hour While Awake After 4 Weeks of Study Treatment
The number of coughs per hour while awake was measured using a cough monitor.
Time frame: Baseline to Week 4
Percent Change in Number of Coughs Per Hour While Asleep Following 4 Weeks of Study Treatment
Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while asleep at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while asleep at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.
Time frame: Baseline to Week 4
Change From Baseline in Weekly Cough Severity Following 4 Weeks of Study Treatment
Cough severity was assessed by the participant by a visual analog scale with numbers from 0 to 100. Results are presented as change from baseline. Reported change is based on a mixed model for the change in weekly cough severity score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the severity score at baseline as covariates. Higher scores indicated higher cough severity.
Time frame: Baseline to Week 4
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score
The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 21. Higher score indicates a better quality of life. Results are presented as change from baseline. Reported change is based on a mixed model for the change in LCQ Total Score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the LCQ Score of corresponding domain at baseline as covariates.
Time frame: Baseline to Week 4
Number of Responders Defined as Participants With an Increase in LCQ of ≥ 1.3 Points
The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 2. A higher score indicates a better quality of life.
Time frame: Baseline to Week 4
Change From Baseline in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)
The ICIQ-SF is a questionnaire used to evaluate the frequency, severity, and impact of urinary incontinence on the quality of life. The questionnaire includes 3 items with responses measured on Likert scales, and 1 item that is measured via a qualitative response. The 3 nominal responses are summed to give the ICIQ score (this total ICIQ-SF score can range from 0 to 21), where a higher score indicates more severe symptoms. The 1 item remaining that is measured via qualitative response is not given a score; rather, the participant selects 1 description out of 8 possible descriptions of this item.
Time frame: Baseline to Week 4
Change From Baseline in Short Form (36) Health Survey (SF-36)
The SF-36 is a 36-item questionnaire to assesses a participant's health status using 8 health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. The mental component reports the average of all the emotionally relevant items and the physical component reports the average of all the physically relevant items. Each component is directly transformed into a 0 to 100 scale on the assumption that each question carries equal weight. A score of 0 is equal to maximum disability, and a score of 100 indicates no disability. Median change can range from -100 to 100. A positive median change indicates an improved outcome.
Time frame: Baseline to Week 4
Number of Responders as Assessed by Patient Global Impression of Change (PGIC)
The PGIC is a patient-reported measure of overall health status and consists of 1 item adapted from the Clinical Global Impressions scale. The participant selects 1 description out of 7 possible descriptions of this item. The descriptions are numbered from 1 through 7, where lower numbers indicate better quality of life. Participants were considered responders if they reported "Very much improved", "Much improved", or "Minimally improved" from baseline on the PGIC assessment.
Time frame: Week 4
| Milestone | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Started | 101 | 103 | 100 | 102 |
| Received at least 1 dose of study drug | 100 | 103 | 100 | 102 |
| Completed | 100 | 99 | 92 | 99 |
| Not completed | 1 | 4 | 8 | 3 |
| Withdrew: Covid-19 reason other than ae | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 2 | 0 |
| Withdrew: Adverse event | 1 | 1 | 4 | 3 |
Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour in 24 hours at each visit with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the log-transformed coughs per hour in 24 hours at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.
| percentage change | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment | -55.16 (-62.80 to -45.94) | -61.08 (-67.71 to -53.08) | -65.32 (-71.37 to -57.99) | -60.38 (-67.07 to -52.32) |
The number of coughs per hour for 24 hours was measured using a cough monitor.
| Participants | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| ≥ 30% Reduction | 55 | 66 | 66 | 61 |
| ≥ 50% Reduction | 38 | 46 | 50 | 49 |
| ≥ 70% Reduction | 24 | 26 | 31 | 27 |
Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while awake at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while awake at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.
| percentage change | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Number of Coughs Per Hour While Awake Following 4 Weeks of Study Treatment | -55.77 (-63.61 to -46.25) | -61.75 (-68.52 to -53.52) | -66.33 (-72.43 to -58.89) | -60.31 (-62.27 to -51.87) |
The number of coughs per hour while awake was measured using a cough monitor.
| Participants | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| ≥ 30% Reduction | 55 | 67 | 67 | 61 |
| ≥ 50% Reduction | 41 | 48 | 51 | 46 |
| ≥ 70% Reduction | 22 | 26 | 29 | 25 |
Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while asleep at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while asleep at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.
| percentage change | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Number of Coughs Per Hour While Asleep Following 4 Weeks of Study Treatment | -54.43 (-66.61 to -37.80) | -53.17 (-65.89 to -35.73) | -65.48 (-74.96 to -52.41) | -52.73 (-65.30 to -35.61) |
Cough severity was assessed by the participant by a visual analog scale with numbers from 0 to 100. Results are presented as change from baseline. Reported change is based on a mixed model for the change in weekly cough severity score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the severity score at baseline as covariates. Higher scores indicated higher cough severity.
| score on a scale | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Weekly Cough Severity Following 4 Weeks of Study Treatment | -19.99 (-24.47 to -15.51) | -22.95 (-27.42 to -18.47) | -28.29 (-32.86 to -23.72) | -21.74 (-26.20 to -17.27) |
The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 21. Higher score indicates a better quality of life. Results are presented as change from baseline. Reported change is based on a mixed model for the change in LCQ Total Score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the LCQ Score of corresponding domain at baseline as covariates.
| score on a scale | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score | 2.80 (2.17 to 3.43) | 3.10 (2.46 to 3.75) | 3.86 (3.19 to 4.53) | 3.17 (2.52 to 3.82) |
The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 2. A higher score indicates a better quality of life.
| Participants | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Number of Responders Defined as Participants With an Increase in LCQ of ≥ 1.3 Points | 53 | 56 | 60 | 48 |
The ICIQ-SF is a questionnaire used to evaluate the frequency, severity, and impact of urinary incontinence on the quality of life. The questionnaire includes 3 items with responses measured on Likert scales, and 1 item that is measured via a qualitative response. The 3 nominal responses are summed to give the ICIQ score (this total ICIQ-SF score can range from 0 to 21), where a higher score indicates more severe symptoms. The 1 item remaining that is measured via qualitative response is not given a score; rather, the participant selects 1 description out of 8 possible descriptions of this item.
| score on a scale | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Baseline, Female With Symptoms | 9.9 ± 5.0 | 8.8 ± 5.2 | 9.2 ± 4.6 | 8.6 ± 4.2 |
| Change at Week 4 - Female With Symptoms | -2.2 ± 3.9 | -1.2 ± 3.4 | -1.6 ± 3.8 | -1.2 ± 3.3 |
| Baseline, Female Without Symptoms | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Change at Week 4 - Female Without Symptoms | 0.9 ± 2.2 | 0.1 ± 0.4 | 0.5 ± 1.3 | 0.3 ± 1.1 |
| Baseline, Male With Symptoms | 9.5 ± 5.3 | 5.0 ± 2.3 | 6.7 ± 4.0 | 5.0 ± 2.2 |
| Change at Week 4 - Male With Symptoms | -2.0 ± 8.3 | -0.7 ± 2.7 | -1.0 ± 2.3 | -0.9 ± 2.2 |
| Baseline, Male Without Symptoms | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Change at Week 4 - Male Without Symptoms | 0.8 ± 2.4 | 1.3 ± 3.2 | 0.5 ± 1.4 | 0.0 ± 0.0 |
The SF-36 is a 36-item questionnaire to assesses a participant's health status using 8 health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. The mental component reports the average of all the emotionally relevant items and the physical component reports the average of all the physically relevant items. Each component is directly transformed into a 0 to 100 scale on the assumption that each question carries equal weight. A score of 0 is equal to maximum disability, and a score of 100 indicates no disability. Median change can range from -100 to 100. A positive median change indicates an improved outcome.
| score on a scale | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Baseline - Physical Component Score | 38.4 ± 6.3 | 38.6 ± 5.7 | 38.1 ± 5.6 | 37.8 ± 5.5 |
| Change at Week 4 - Physical Component Score | -0.3 ± 5.0 | -0.9 ± 4.5 | -0.9 ± 4.6 | -1.3 ± 5.0 |
| Baseline - Mental Component Score | 46.1 ± 10.3 | 47.1 ± 9.0 | 47.5 ± 8.7 | 47.2 ± 9.2 |
| Change at Week 4 - Mental Component Score | 2.2 ± 5.9 | 1.9 ± 6.0 | 2.6 ± 6.0 | 3.3 ± 6.0 |
The PGIC is a patient-reported measure of overall health status and consists of 1 item adapted from the Clinical Global Impressions scale. The participant selects 1 description out of 7 possible descriptions of this item. The descriptions are numbered from 1 through 7, where lower numbers indicate better quality of life. Participants were considered responders if they reported "Very much improved", "Much improved", or "Minimally improved" from baseline on the PGIC assessment.
| Participants | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| Number of Responders as Assessed by Patient Global Impression of Change (PGIC) | 57 | 72 | 79 | 65 |
Collected over Up to 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| S-600918 50 mg | 0/101 (0%) | 0/101 (0%) | 5/101 (5%) |
| S-600918 150 mg | 0/103 (0%) | 0/103 (0%) | 15/103 (14.6%) |
| S-600918 300 mg | 0/100 (0%) | 0/100 (0%) | 34/100 (34%) |
| Placebo | 0/102 (0%) | 0/102 (0%) | 10/102 (9.8%) |
| Event | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo |
|---|---|---|---|---|
| DysgeusiaNervous system disorders | 2/101 | 12/103 | 27/100 | 3/102 |
| HeadacheNervous system disorders | 3/101 | 2/103 | 1/100 | 7/102 |
| HypogeusiaNervous system disorders | 0/101 | 1/103 | 6/100 | 0/102 |
Full Analysis Set included all randomized participants who received at least 1 dose of study drug and who had cough monitor assessment at both baseline and at least 1 visit after initiation of study drug administration.
| Age, Continuous(years) | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 58.7 ± 11.2 | 57.2 ± 12.5 | 56.1 ± 12.4 | 56.1 ± 11.5 | 57.0 ± 11.9 |
| Sex: Female, Male(Participants) | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 78 | 75 | 65 | 77 | 295 |
| Male | 22 | 27 | 31 | 25 | 105 |
| Ethnicity (NIH/OMB)(Participants) | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 4 | 2 | 14 |
| Not Hispanic or Latino | 95 | 98 | 92 | 100 | 385 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 2 | 2 |
| Asian | 25 | 25 | 25 | 22 | 97 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 1 | 4 | 9 |
| White | 71 | 76 | 69 | 72 | 288 |
| More than one race | 1 | 0 | 1 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Average Coughs per Hour in 24 Hours(number of coughs) | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 30.40 ± 22.92 | 40.95 ± 64.68 | 36.21 ± 37.91 | 33.85 ± 34.60 | 35.36 ± 43.00 |
| Weekly Severity of Cough(score on a scale) | S-600918 50 mg | S-600918 150 mg | S-600918 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 74.8 ± 14.0 | 73.6 ± 13.8 | 72.6 ± 15.3 | 71.6 ± 14.5 | 73.1 ± 14.4 |
Showing the first 100 of 136 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2020 to primary completion in Dec 2020, 9 months.
Results were first posted in Mar 2024, 3 years 3 months after primary completion. A results delay was requested in Dec 2021.
Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.